Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Dr Reddy’s debuts biosimilar bevacizumab in India but can the significant price differential for one strength of the product help it gnaw into a competitive market?

The arrest of India's deputy drugs controller creates shock waves and indicates an intent to clamp down on graft at any level, say industry experts.

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.